Abstracts tagged "Adalimumab and uveitis"

Abstract Number: 2271 • 2018 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Adalimumab By Immunosuppressant Use in Patients with Non-Infectious Uveitis
Yan Guex-Crosier¹, C. Stephen Foster², Kei Nakai³, Hiroshi Goto⁴, Kevin Douglas⁵, Sophia Pathai⁶, Martina Kron⁷, Alexandra P. Song⁵, Joachim Van Calster⁸ and Alfredo Adan⁹, ¹Jules Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland, ²Massachusetts Eye Research and Surgery Institution (MERSI), Ocular Immunology & Uveitis Foundation (OIUF), Waltham, MA, USA and Harvard Medical School, Boston, MA, ³Yodogawa Christian Hospital, Osaka, Japan, ⁴Tokyo Medical University, Tokyo, Japan, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Ltd, Maidenhead, United Kingdom, ⁷AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁸University Hospitals Leuven, Leuven, Belgium, ⁹Hospital Clinic. Barcelona. Spain, Barcelona, Spain
Background/Purpose: To evaluate the long-term safety and efficacy of adalimumab in patients with non-infectious intermediate, posterior, or panuveitis, by immunosuppressant (IMM) use. Methods: Adult patients…
Abstract Number: 2723 • 2017 ACR/ARHP Annual Meeting
Adalimumab Therapy Optimization in Refractory Uveitis Due to Behçet’s Disease after Achieving Remission. interventional Versus Control Group
Belén Atienza-Mateo¹, José Luis Martín-Varillas¹, Nuria Vegas-Revenga¹, Lucia C. Domínguez-Casas¹, Vanesa Calvo-Río¹, Emma Beltrán², Juan Sánchez-Burson³, Marina Mesquida⁴, Alfredo Adán⁴, M Victoria Hernández⁴, Marisa Hernández Garfella², Elia Valls Pascual⁵, Lucía Martínez Costa⁵, Agustí Sellas-Fernandez⁶, Miguel Cordero Coma⁷, Manuel Díaz-Llopis⁸, Roberto Gallego⁸, David Salom⁸, Norberto Ortego⁹, José L. García-Serrano⁹, José-Luis Callejas-Rubio⁹, José M. Herreras¹⁰, Ángel M García-Aparicio¹¹, Olga Maíz¹², Ana Blanco¹³, Ignacio Torre¹⁴, David Díaz Valle¹⁵, Esperanza Pato¹⁵, Elena Aurrecoechea¹⁶, Miguel A. Caracuel¹⁷, Fernando Gamero¹⁸, Enrique Mínguez¹⁹, Carmen Carrasco Cubero²⁰, Alejandro Olive²¹, Julio Vázquez²², Oscar Ruiz Moreno²³, Fernando Jiménez-Zorzo²⁴, Javier Manero²⁴, Myriam Gandia Martinez²⁵, Esteban Rubio-Romero²⁶, F. Javier Toyos-Sáenz de Miera²⁷, Javier López-Longo²⁸, JM Nolla²⁹, Marcelino Revenga³⁰, Rosalia Demetrio³¹, Enar Pons³¹, Miguel Angel González-Gay¹ and Ricardo Blanco³², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital General Universitario de Valencia, Valencia, Spain, ³Hospital de Valme, Sevilla, Spain, ⁴Hospital Clinic, Barcelona, Spain, ⁵Hospital Peset, Valencia, Spain, ⁶Hospital Vall d´Hebron, Barcelona, Spain, ⁷Hospital de León, León, Spain, ⁸Hospital Universitario La Fe, Valencia, Spain, ⁹Hospital San Cecilio, Granada, Spain, ¹⁰Hospital Universitario IOBA, Valladolid, Spain, ¹¹Hospital Donosti, San Sebastián, Spain, ¹²Hospital Donosti, San Sebastian, Spain, ¹³Ophthalmology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, ¹⁴Hospital Basurto, Bilbao, Spain, ¹⁵Hospital Clínico San Carlos, Madrid, Spain, ¹⁶Hospital Sierrallana, Torrelavega, Spain, ¹⁷Hospital Córdoba, Córdoba, Spain, ¹⁸Hospital San Pedro Alcántara, Cácerer, Spain, ¹⁹Hospital Clínico Zaragoza, Zaragoza, Spain, ²⁰Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ²¹Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ²²Hospital de Ferrol, A Coruña, Spain, ²³Ophthalmology and Rheumatology., Ophtalmology. Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ²⁴Hospital Miguel Servet, Zaragoza, Spain, ²⁵Hospital Puerta del Mar, Cádiz, Spain, ²⁶Hospital Universitario Virgen del Rocío, Sevilla, Spain, ²⁷Hospital Universitario Virgen Macarena, Sevilla, Spain, ²⁸Hospital Gregorio Marañón, Madrid, Spain, ²⁹Hospital Universitari de Bellvitge, Barcelona, Spain, ³⁰Hospital Universitario Ramón y Cajal, Madrid, Spain, ³¹Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria., Santander, Spain, ³²Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Adalimumab (ADA) therapy has been approved by the EMA and the FDA in non-infectious and non-anterior uveitis. After loading, the maintenance dose is 40…
Abstract Number: 1335 • 2016 ACR/ARHP Annual Meeting
Long–Term Safety and Efficacy of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis in an Ongoing Open-Label Study
Eric B. Suhler¹, Glenn J. Jaffe², Quan Dong Nguyen³, Antoine P. Brezin⁴, Manfred Zierhut⁵, Albert Vitale⁶, Mirjam van Velthoven⁷, Alfredo Adan⁸, Lyndell Lim⁹, Michal Kramer¹⁰, Ariel Schlaen¹¹, Eric Fortin¹², Cristina Muccioli¹³, Hiroshi Goto¹⁴, Toshikatsu Kaburaki¹⁵, Anne Camez¹⁶, Alexandra P. Song¹⁷, Martina Kron¹⁶, Samir Tari¹⁷ and Andrew D. Dick¹⁸, ¹Oregon Health & Science University, Casey Eye Institute, and VA Portland Health Care System, Portland, OR, ²Duke University, Durham, NC, ³Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, ⁴Université Paris Descartes, Hôpital Cochin, Paris, France, ⁵Center of Ophthalmology, University of Tuebingen, Tuebingen, Germany, ⁶University of Utah, Salt Lake City, UT, ⁷Rotterdam Eye Hospital, Rotterdam, Netherlands, ⁸Ophthalmology, Hospital Clinic de Barcelona,, Barcelona, Spain, ⁹Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia, ¹⁰Rabin Medical Center, Petach Tikva, Tel Aviv University, Tel Aviv, Israel, ¹¹Austral University, Buenos Aires, Argentina, ¹²University of Montreal, Montreal, QC, Canada, ¹³Federal University of São Paulo, São Paulo, Brazil, ¹⁴Tokyo Medical University, Tokyo, Japan, ¹⁵Ophthalmology, The University of Tokyo School of Medicine, Bunkyo-ku, Japan, ¹⁶Abbvie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ¹⁷AbbVie Inc., North Chicago, IL, ¹⁸University of Bristol, Bristol Eye Hospital; National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital and University College London, Institute of Ophthalmology, London, United Kingdom
Background/Purpose: To evaluate the long-term safety and efficacy of adalimumab (Humira®) in patients with non-infectious intermediate, posterior, or panuveitis (NIPPU) in an open-label clinical trial…
Abstract Number: 3077 • 2016 ACR/ARHP Annual Meeting
Quiescence in Active and Inactive Non-Infectious, Intermediate, Posterior, or Panuveitis in Patients Treated with Adalimumab
Robert Landewé¹, Irene van der Horst-Bruinsma², Samir Tari³, Stefan Florentinus³, Alexandra P. Song³, Martina Kron⁴, Sophia Pathai⁵ and James T. Rosenbaum^6,7, ¹University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴Abbvie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ⁵AbbVie Ltd, Maidenhead, United Kingdom, ⁶Casey Eye Institute, Oregon Health & Science University, Portland, OR, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: There is an unmet need for effective therapies for patients (pts) with non-infectious intermediate, posterior, or panuveitis who are at risk for long-term side…
Abstract Number: 1388 • 2015 ACR/ARHP Annual Meeting
Adalimumab in Patients with Inactive, Non-Infectious Uveitis Requiring Systemic Treatment
Quan Dong Nguyen¹, Shree Kumar Kurup², Pauline Merrill³, John Sheppard⁴, Joachim Van Calster⁵, Andrew D Dick⁶, Glenn Jaffe⁷, Friederike Mackensen⁸, James T. Rosenbaum^9,10, Ariel Schlaen¹¹, Anne Camez¹², Samir Tari¹³, Martina Kron¹², Alexandra Song¹³ and Antoine Brezin¹⁴, ¹Truhlsen Eye Institute, University of Nebraska, Omaha, NE, ²Wake Forest Baptist Medical Center, Winston-Salem, NC, ³Rush University Medical Center, Chicago, IL, ⁴Lions Medical Eye Bank of Eastern Virginia, Norfolk, VA, ⁵University Hospitals Leuven, Leuven, Belgium, ⁶Bristol Eye Hospital, Bristol, United Kingdom, ⁷Duke University, Durham, NC, ⁸Heidelberg University Hospital, Heidelberg, Germany, ⁹Dever's Eye Institute, Legacy Hospital, Portland, OR, ¹⁰Division of Rheumatology, Oregon Health and Science University, Portland, OR, ¹¹Austral University, Buenos Aires, Argentina, ¹²Abbvie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ¹³AbbVie Inc., North Chicago, IL, ¹⁴Université Paris Descartes, Hôpital Cochin, Paris, France
Background/Purpose: To assess adalimumab (ADA) efficacy and safety in corticosteroid-dependent patients with inactive non-infectious, intermediate, posterior, or panuveitis enrolled in the international, double-masked trial, VISUAL…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].